Skip to main content
. 2021 Mar 5;7:25. doi: 10.1038/s41523-021-00233-9

Fig. 3. Upgrade and downgrade rates following neoadjuvant therapy by clinical node status.

Fig. 3

Pathologic node status following neoadjuvant chemotherapy or endocrine therapy in clinically node negative and positive patients.